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Abstract
Background: Cocaine and crack use has been associated with HIV and HCV infections, but its consequences on
HCV progression have not been well established. We analyzed the impact of cocaine/crack use on liver fibrosis
progression in a cohort of HIV-HCV co-infected patients.
Methods: A Canadian multicenter prospective cohort study followed 1238 HIV-HCV co-infected persons every
6 months between 2003 and 2013. Data were analyzed from 573 patients with positive HCV RNA, not on HCV
treatment, without significant liver fibrosis (AST-to-Platelet Ratio Index (APRI) <1.5) or history of end-stage liver
disease at baseline, and having at least two study visits. Recent cocaine/crack use was defined as use within
6 months of cohort entry. Incidence rates of progression to significant fibrosis (APRI ≥ 1.5) were determined
according to recent cocaine/crack use. Cox Proportional Hazards models were used to assess the association
between time-updated cocaine/crack use and progression to APRI ≥ 1.5 adjusting for age, sex, HCV duration,
baseline ln(APRI), and time-updated alcohol abuse, history of other drug use and CD4+ cell count.
Results: At baseline, 211 persons (37%) were recent cocaine/crack users and 501 (87%) ever used cocaine/
crack. Recent users did not differ from non-recent users on gender, age, and CD4+ T-cell count. Over 1599
person-years of follow up (522 PY in recent users, 887 PY in previous users and 190 PY in never users),158
(28%) persons developed significant fibrosis (9.9/100 PY; 95% CI, 8.3–11.4); 56 (27%) recent users (10.7/100 PY;
7.9–13.5), 81 (28%) previous users (9.1/100 PY; 7.1–11.1), and 21 (29%) never users (11.1/100 PY; 6.3–15.8).
There was no association between ever having used or time-updated cocaine/crack use and progression to
APRI ≥ 1.5 (adjusted HR (95%CI): 0.96 (0.58, 1.57) and 0.88;(0.63–1.25), respectively).
Conclusions: We could not find evidence that cocaine/crack use is associated with progression to advanced
liver fibrosis in our prospective study of HIV-HCV co-infected patients.
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Background
Worldwide, the number of cocaine/crack users is esti-
mated at 14–21 million people, including 5.7 million
North Americans [1]. Cocaine/crack addiction is a
significant problem in Canada. In the Canadian Alcohol
and Drug Use Monitoring Survey, cocaine use was
reported by 0.9% of persons surveyed in 2011 [2]. In the
I-track study published in 2010, cocaine was the most
frequently injected drug, with 52% percent of injection
drug users (IDU) reporting having used it in the last
6 months [3]. Similarly, in the SurvUDI network study
(2003–2008), 86% of IDU reported injecting cocaine and
68% reported smoking crack/freebase [4].
Cocaine/crack use has been associated with an in-
creased risk of HIV and hepatitis C (HCV) transmis-
sion, even when the drug is not injected [5–7]. This
phenomenon could result from mucous membrane
lesions, sharing of material and at-risk sexual behav-
iours [8]. On the other hand, the impact of cocaine/
crack on the natural history and treatment of HIV
and HCV is an understudied phenomenon. This situ-
ation is due, in part, to the absence of a substitute
for cocaine as compared to methadone and buprenor-
phine for opiates [9]. Nevertheless, it is plausible that
cocaine/crack could accelerate liver fibrosis progres-
sion through vascular damage and recurrent episodes
of ischemic acute hepatitis.
The aim of our study is to determine if cocaine/crack
use is associated with accelerated liver fibrosis progres-
sion among HIV/HCV co-infected patients as measured
by the APRI score.
Methods
Participants
The Canadian Co-Infection Cohort is an open
prospective multi-centre cohort study of HIV/HCV
co-infected individuals (n = 1238) recruited from 18
centers across Canada since 2003. It represents ap-
proximately 20% of the co-infected population under
care in Canada. Inclusion criteria are: ≥16 year old,
documented HIV infection by serological assay con-
firmed by Western blot, HCV infection documented
by serological assay or, in case of false-negative ser-
ology, a positive HCV RNA. Socio-demographic and
behavioral data are collected by self-reported ques-
tionnaires. Medical charts are reviewed for medical
treatments and diagnoses and samples are collected at
baseline and every 6 months. Details of the cohort
can be found elsewhere [10].
Inclusion criteria for this analysis included participants
with chronic HCV infection (positive HCV RNA), not
receiving HCV treatment at baseline, who did not have
significant liver fibrosis (see below) or a history of end-
stage liver disease at baseline and who had at least two
study visits. Patients were followed until their first out-
come occurrence, initiation of HCV treatment or last
study visit before database closure in December 2013.
Cocaine/crack use
The exposure of interest was cocaine/crack use, ei-
ther recent (within 6 months of a study visit), previ-
ous but not within 6 months, or never. Data
concerning drug use were collected at every study
visit. Questions evaluated types of drug used and
routes of administration (injection vs. other) ever and
in the last 6 months.
Outcome: significant liver fibrosis
The AST-to-Platelet Ratio (APRI; (AST/ULN)/plate-
lets × 100) is a non-invasive scoring system allowing
for categorization of patients as free of significant
fibrosis (score ≤ 0.5), with advanced fibrosis (≥1.5) or
with cirrhosis (≥2). The main outcome of interest was
occurrence of significant liver fibrosis defined as an
APRI ≥ 1.5 [11].
Statistical analyses
Descriptive statistics were used to characterize variables
at baseline. Medians and interquartile ranges or numbers
and proportions are reported for continuous and
discrete variables respectively.
The following covariates of interest were measured:
age, sex, ethnicity, income, body mass index (BMI), dia-
betes (determined based on glucose and fasting status),
duration of HCV infection and time since HIV diagnosis
and time updated HIV viral load and CD4+ cell count,
antiretroviral therapy use, IDU, cocaine, crack and alco-
hol abuse in the previous 6 months. HCV duration was
determined as time since first HCV diagnosis test, prob-
able HCV infection according to patient, or first injec-
tion drug use, whichever was greater. Alcohol abuse was
defined as more than six drinks at least once a month or
more than two drinks on a typical day when drinking.
Incidence rates of progression to significant fibrosis
(APRI ≥ 1.5) from baseline (cohort entry) were deter-
mined according to recent cocaine/crack use. Cox Pro-
portional Hazards models were used to assess the
association between time-updated recent cocaine/crack
use and progression to APRI ≥ 1.5, while adjusting for
baseline age, sex, HCV duration, ln(APRI) and previous
use of cocaine/crack at at any time prior the baseline
visit and time-updated current alcohol abuse, use of
other drugs, and CD4+ cell count. The final model was
constructed using covariates selected a priori as likely to
be potential confounders. A sensitivity analysis was also
performed by replicating the primary analysis using an
APRI cut-off of 2 (cirrhosis) rather than 1.5. In case of
missing variables, imputation rules were used. Indicator
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variables were imputed as false, continuous variables
were imputed with their mean or median, depending
on the shape of their distributions. All analyses were
conducted using R version 3.3.0 (R Core Team,
2016).
Results
A total of 573 patients met inclusion criteria of whom,
at baseline, 211 persons (36.8%) were recent cocaine/
crack users, 290 (50.6%) persons previously used co-
caine/crack but were not currently using, and 72 (12.6%)
persons never used cocaine/crack (Fig. 1 and Table 1).
Over the course of follow up, 47% of previous users and
3% of never users became recent users, while 79% of
recent users remained recent users.
Recent cocaine/crack users did not differ from pre-
vious users and never users on gender, age, and time
since HIV diagnosis. At baseline, recent users were
more likely to be be younger and of of Aboriginal
origin, had lower CD4+ T-cells, were more likely to
abuse alcohol, had longer median durations of HCV
infection, but had lower median APRI scores and
were more likely to be HCV treatment naive. The
three groups did not differ with respect to reasons
for censoring except that study withdrawal and HCV
treatment initiations were more frequent among never
users (Table 2).
Over 1599 person-years of follow up (522 PY in recent
cocaine/crack users, 887 PY in previous users, and 190
PY in never users), 158 (28%) persons developed signifi-
cant fibrosis (9.9/100 PY; 95% CI, 8.3–11.4), of whom 56
(27%) were recent users (10.7/100 PY; 7.9–13.5), 81
(28%) were previous users (9.1/100 PY; 7.1–11.1), and 21
(29%) were never users (11.1/100 PY; 6.3–15.8).
Because drug use can change over time, a model was
built with time-updated status for recent cocaine/crack
use and recent other drug use (Table 3). Time-updated
recent cocaine/crack use and ever using cocaine/crack at
baseline were not associated with progression to an
APRI ≥ 1.5 (recent: 0.88 (0.63–1.25) and ever (0.96
(0.58–1.57)). Female sex, higher baseline ln(APRI),
current alcohol abuse, and lower CD4 counts were
significantly associated with the fibrosis progression.
Similarly, cocaine/crack use was not associated with
progression to an APRI ≥ 2 in both time-updated recent
users and previous users at baseline (recent: 0.69 (0.45–
1.04) and ever: 0.83 (0.50–1.40)) (Table 4). Female sex,
higher baseline ln(APRI score), current alcohol abuse,
and lower CD4 count were also associated with achiev-
ing and APRI ≥ 2.
Discussion
In this longitudinal study of liver fibrosis progression in
HIV-HCV co-infected patients, we were unable to
demonstrate an association between cocaine/crack use
and evolution of liver fibrosis as measured by APRI
score. Not surprisingly, alcohol abuse, CD4 cell count
and baseline APRI score were predictors of progression
to advanced fibrosis. The association between female sex
and liver fibrosis progression although not generally seen
in HCV mono-infection was previously noted in the
Canadian Co-infection cohort and other co-infected
studies [12, 13].
The influence of cocaine on liver pathology has been
studied in animal models. Cocaine has been associated
with parenchymal necrosis and microvesicular changes
in hepatic architecture [14]. Cocaine is metabolised in
the liver by CYP450 to norcocaine [15]. Norcocaine is
then transformed into free radicals which cause liver
damage [14]. Decreased ATPase activity in isolated rat
liver mitochondria was also reported [16]. In addition,
liver damage can result from damage to other organs
through hyperpyrexia, hypotension and rhabdomyolysis
[15, 17].
With respect to fibrosis and liver function, data
from clinical human studies are currently limited. In
a retrospective study, transplant recipients who re-
ceived a liver from a donor who was a cocaine user
had higher levels of prothrombin time and AST on
post-operative day one and more graft loss within 3
months as compared to recipients of livers from non-
cocaine users [14]. There was also more primary non-
function and lower graft survival in the cocaine
group. One potential confounder in this study was
that cocaine users were also more likely to drink
alcohol. Nevertheless, the study suggests at least a
subclinical impact of cocaine on liver function [14].
On the other hand, Foucher et al. study contra-
dicts the hypothesis of accelerated liver disease pro-
gression among cocaine users [18]. Cocaine-snorting
was not associated with elevated transient elastogra-
phy scores in their study performed on 298 drug
users. However, those who never snorted cocaine
and had less than 21 drinks per week were more
likely to be HCV seropositive raising concerns about
the generalizability of these findings [18]. Multiple
other studies have shown a high correlation between
cocaine use and HCV infection, [19, 20] although
none has investigated the effect of cocaine on liver
disease progression.
Our study is the first to evaluate systematically the
presence of an association between cocaine/crack use
and liver fibrosis. This was done in a large prospect-
ive cohort of HIV-HCV co-infected patients, represen-
tative of the population of co-infected patients in care
in Canada. We controlled for major known con-
founders that could be linked with cocaine use and
liver disease risk.
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Fig. 1 a Sample Selection Flow Chart. b Sample Selection Flow Chart Stratified by Group Legend: cc: Cocaine/crack
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Among study limitations, the most important is that
data about quantity and route of administration other
than injection are not collected in our study question-
naire. Consequently, we cannot exclude a dose-related
effect of cocaine/crack on liver fibrosis. Concerning
route of administration, we chose to combine all routes
of administration together based on previous studies
showing that similar serum concentrations are
achieved when these drugs are injected and smoked
although some studies suggest snorted cocaine leads
to lower plasma drug concentration [21]. Because al-
most the entire patient population (87%) had used co-
caine or crack at some time, focusing only on recent
use could miss potential long-term effects of cocaine
on the liver. In order to account for consumption
changes over time, we used a time-updated variable
for recent cocaine/crack use. However, we did not
have a measure of duration or intensity of such drug
use prior to cohort entry.
Arguably APRI score is an imperfect surrogate for
liver fibrosis and is not the gold standard for liver
fibrosis evaluation. Nevertheless, because of cost and
potential safety risks, it is not possible to perform







n = 211 n = 290 n = 72
Outcome (APRI≥ 1.5) 56 (27%) 81 (28%) 21 (29%)
End of study period 99 (47%) 96 (33%) 21 (29%)
HCV Treatment
initiation
15 (7%) 37 (13%) 13 (18%)
Death 11 (5%) 24 (8%) 2 (3%)
Lost to follow-up 23 (11%) 33 (11%) 7 (10%)
Withdrawal 7 (3%) 19 (7%) 8 (11%)





Time independent variables (at baseline)
Cocaine/crack use ever at baseline 0.96 0.58, 1.57
Baseline age (per 10 years) 1.04 0.86, 1.27
Female sex 1.45 1.04, 2.01
Baseline HCV infection duration (per 5 years) 1.00 0.92, 1.10
Baseline ln (APRI) 2.84 1.94, 4.16
Time updated variables
Recent cocaine/crack use 0.88 0.63, 1.25
Recent other drug usea 1.07 0.77, 1.49
Current alcohol abuseb 1.63 1.09, 2.42
CD4 count (per 100 cells/μL) 0.90 0.84, 0.96
aHeroin and opiates, steroids, methylphenidate, hallucinogens (PCP, LSD),
benzodiazepine, barbiturates, methamphetamine, amphetamine, other
bDefined as >6 drinks at least once a month and >2 drinks on a typical day
when drinking
Table 1 Baseline characteristics of study population
Total (N = 573) Recent cocaine/crack
use (N = 211)
Previously used cocaine/crack;
not recent (N = 290)
Never used cocaine/
crack (N = 72)
Follow-up time (years)a 2.3 (1.0, 4.1) 2.1 (1.0, 3.9) 2.4 (1.1, 4.5) 2.0 (0.8, 4.4)
Age (years) 44 (38, 49) 43 (38, 49) 44 (38, 48) 47 (40, 53)
Female 173 (30%) 69 (33%) 81 (28%) 23 (32%)
Aboriginal 86 (15%) 53 (25%) 31 (11%) 2 (3%)
Time since HIV diagnosis (years) 10 (5, 16) 10 (5, 14) 10 (6, 16) 13 (5, 20)
Duration HCV infection (years) 18 (10, 25) 19 (12, 26) 18 (11, 25) 10 (4, 20)
CD4 cell count (cells/μL) 389 (253, 550) 360 (220, 528) 390 (260, 550) 439 (300, 601)
HIV RNA load≤ 50 copies/mL 340 (59%) 117 (55%) 175 (60%) 48 (67%)
Time since first start of ART (years) 6 (2, 11) 6 (2, 10) 6 (3, 11) 9 (2, 12)
cART regimen 453 (79%) 164 (78%) 227 (78%) 62 (86%)
Prior AIDS diagnosis 162 (28%) 65 (31%) 77 (27%) 20 (28%)
APRI 0.5 (0.4, 0.8) 0.5 (0.4, 0.7) 0.6 (0.4, 0.8) 0.6 (0.4, 1.0)
HCV RNA (log10 UI/mL)
b 6.2 (5.4, 6.7) 6.1 (5.1, 6.6) 6.2 (5.5, 6.8) 6.2 (5.6, 6.7)
HCV treatment naïve 512 (89%) 197 (93%) 258 (89%) 57 (79%)
Alcohol abusec 83 (14%) 41 (19%) 37 (13%) 5 (7%)
a: Median (IQR) or Number (%)
b: For HCV RNA only 307 (86/211 (41%) recent cocaine/crack users, 170/290 (59%) previous/not recent cocaine/crack users, and 51/72 (71%) non cocaine/crack
users) had available quantitative HCV RNA values
c: Defined as >6 drinks at least once a month and >2 drinks on a typical day when drinking
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repetitive liver biopsy in a cohort study. In addition,
even if transient elastography is now considered as a
validated non-invasive test for liver fibrosis and is
well suited for repeated testing, it was not available
when the cohort was formed and is still not available
to all our study sites. APRI is widely used in clinical
practice and has been recommended by the World
Health Organization [22]. Despite a meta-analysis
showing a trend toward less accurate results for APRI
in co-infected than mono-infected patients, this dif-
ference was not significant in meta-regression analysis
and APRI has been validated in our HIV/HCV co-
infected patients [11, 23]. Multiple studies have used
the APRI score and demonstrated its value in predict-
ing liver fibrosis progression, hepatic decompensation
and death [11, 24–27]. The APRI score has been
shown to perform similarly to other markers of liver
fibrosis including FIB-4 [28]. The APRI score lacks
sensitivity and may misclassify individuals as not hav-
ing fibrosis, however is highly specific for fibrosis
stage ≥ F2 (0.93, 95% CI: 0.91, 0.94) [23]. Thus using
APRI ≥1.5 as an outcome is conservative. While we
may have underestimated the degree of fibrosis
present among those with scores below 1.5, any such
under-ascertainment is unlikely to vary by exposure
to cocaine. Nevertheless, because there is some con-
troversy concerning the clinical significance of pro-
gression to an APRI ≥ 1.5, we conducted a sensitivity
analysis with an APRI cut-off value of 2, correspond-
ing to liver cirrhosis. Similar to the other models, re-
cent cocaine/crack use or ever using cocaine/crack
was not associated with APRI progression.
Conclusions
In conclusion, while cocaine/crack use is certainly asso-
ciated with high-risk behaviours related to HCV infec-
tion and to potential acute liver injury, we were unable
to demonstrate an association between these drugs and
chronic liver fibrosis progression.
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Time independent variables (at baseline)
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